Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. GALLIUM CITRATE (GA 67) INJECTION 37 MBQ/ML [SIN09913P]

GALLIUM CITRATE (GA 67) INJECTION 37 MBQ/ML [SIN09913P]

Active ingredients: GALLIUM CITRATE (GA 67) INJECTION 37 MBQ/ML

Last updated 26 October 2025

Product Info

GALLIUM CITRATE (GA 67) INJECTION 37 MBQ/ML

[SIN09913P]

Product information

Active Ingredient and Strength

GALLIUM CITRATE EQV GA67 - 37 MBQ/ML AT ART

Dosage Form

INJECTION

Manufacturer and Country

CURIUM NETHERLANDS B.V. - NETHERLANDS

Registration Number

SIN09913P

Licence Holder

QT INSTRUMENTS (S) PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

V09HX01

Indications
Scintigraphy with gallium-67 is indicated in:

  • the clinical evaluation of patients suspected of neoplastic diseases, notably Hodgkin’s disease, other malignant lymphomas, soft tissue sarcomas and most bronchogenic carcinomas.

  • the localisation of metastases of malignant melanomas.

  • the differentiation of hepatoma and liver metastases, and pleural and peritoneal mesotheliomas.

  • determining the extent of involvement of malignancy.

  • the follow-up of tumour therapy and screening for recurrent tumour.

  • the localisation of focal inflammatory lesions and the evaluation of fever of unknown origin.

Dosage and administration
Usual dose 74–111 MBq (2–3mCi) by intravenous injection.

Contraindications
Gallium Citrate (Ga-67) Injection is contraindicated in lactating mothers unless the child is formula-fed for a period of at least three weeks after the injection.
No other contraindications are known.